Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

This study tests a drug called epcoritamab — a bispecific antibody that helps the immune system attack lymphoma cells — as a first-time treatment for patients newly diagnosed with a type of slow-growing blood cancer called Marginal Zone Lymphoma (MZL). Epcoritamab is given as an injection under the skin. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Marginal Zone Lymphoma (MZL) — including extranodal, nodal, or splenic subtypes — at any stage - You have not previously received treatment for MZL (some exceptions apply for localized therapy or antibiotic treatment of stomach MZL) - You are willing and able to follow the study requirements **You may NOT be eligible if...** - You have received prior systemic treatment for MZL - You have significant organ problems or conditions that make the study unsafe - You have another active cancer Talk to your doctor to see if this trial is right for you.